ATE359087T1 - Verwendung von erythropoietin zur behandlung oder vorbeugung von herzversagen - Google Patents
Verwendung von erythropoietin zur behandlung oder vorbeugung von herzversagenInfo
- Publication number
- ATE359087T1 ATE359087T1 AT03703525T AT03703525T ATE359087T1 AT E359087 T1 ATE359087 T1 AT E359087T1 AT 03703525 T AT03703525 T AT 03703525T AT 03703525 T AT03703525 T AT 03703525T AT E359087 T1 ATE359087 T1 AT E359087T1
- Authority
- AT
- Austria
- Prior art keywords
- erythropoietin
- treat
- heart failure
- prevent heart
- suffering
- Prior art date
Links
- 102000003951 Erythropoietin Human genes 0.000 title abstract 2
- 108090000394 Erythropoietin Proteins 0.000 title abstract 2
- 206010019280 Heart failures Diseases 0.000 title abstract 2
- 229940105423 erythropoietin Drugs 0.000 title abstract 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 title abstract 2
- 238000009109 curative therapy Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000003449 preventive effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Cardiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL0200010 | 2002-01-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE359087T1 true ATE359087T1 (de) | 2007-05-15 |
Family
ID=19760786
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03703525T ATE359087T1 (de) | 2002-01-09 | 2003-01-09 | Verwendung von erythropoietin zur behandlung oder vorbeugung von herzversagen |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7335490B2 (de) |
| EP (1) | EP1471930B1 (de) |
| CN (1) | CN1612747A (de) |
| AT (1) | ATE359087T1 (de) |
| AU (1) | AU2003206251B2 (de) |
| CA (1) | CA2476538C (de) |
| DE (1) | DE60313125T2 (de) |
| WO (1) | WO2003057242A1 (de) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7297680B2 (en) * | 1999-04-15 | 2007-11-20 | Crucell Holland B.V. | Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content |
| WO2003057242A1 (en) | 2002-01-09 | 2003-07-17 | Crucell Holland B.V. | Use of erythropoietin for the preventive or curative treatment of cardiac failure |
| DE10219545A1 (de) * | 2002-04-26 | 2003-11-06 | Lang Florian | Regulation der Apoptose |
| DE10234192B4 (de) * | 2002-07-26 | 2009-11-26 | Epoplus Gmbh Co.Kg | Verwendung von Erythropoetin |
| DE102004063927A1 (de) * | 2004-01-23 | 2005-12-15 | Epoplus Gmbh Co.Kg | Einsatz von niedrig dosiertem Erythropoietin zur Stimulation endothelialer Vorläuferzellen sowie zur Organregeneration und Progressionsverlangsamung von Endorganschäden |
| US8067365B2 (en) * | 2004-11-22 | 2011-11-29 | University Of Utah Research Foundation | Erythropoietin for treatment of multi-organ failure |
| DE102005003632A1 (de) | 2005-01-20 | 2006-08-17 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Katheter für die transvaskuläre Implantation von Herzklappenprothesen |
| AR053416A1 (es) | 2005-11-10 | 2007-05-09 | Protech Pharma S A | Combinacion de glicoisoformas para el tratamiento o prevencion de la septicemia, linea celular transgenica productora de glicoformas de eritropoyetina, composicion farmaceutica que comprende a dicha combinacion, procedimientos para obtener la linea celular, procedimiento para producir dicha combinac |
| US20070213813A1 (en) | 2005-12-22 | 2007-09-13 | Symetis Sa | Stent-valves for valve replacement and associated methods and systems for surgery |
| US7896915B2 (en) | 2007-04-13 | 2011-03-01 | Jenavalve Technology, Inc. | Medical device for treating a heart valve insufficiency |
| US9044318B2 (en) | 2008-02-26 | 2015-06-02 | Jenavalve Technology Gmbh | Stent for the positioning and anchoring of a valvular prosthesis |
| ES2903231T3 (es) | 2008-02-26 | 2022-03-31 | Jenavalve Tech Inc | Stent para el posicionamiento y anclaje de una prótesis valvular en un sitio de implantación en el corazón de un paciente |
| US20100261224A1 (en) * | 2009-04-10 | 2010-10-14 | Felsher Dean W | Discovery and validation of cancer biomarkers using a protein analysis methodology to analyze specimens |
| US10856978B2 (en) | 2010-05-20 | 2020-12-08 | Jenavalve Technology, Inc. | Catheter system |
| CA2799459A1 (en) | 2010-05-25 | 2011-12-01 | Jenavalve Technology Inc. | Prosthetic heart valve and transcatheter delivered endoprosthesis comprising a prosthetic heart valve and a stent |
| WO2015028209A1 (en) | 2013-08-30 | 2015-03-05 | Jenavalve Technology Gmbh | Radially collapsible frame for a prosthetic valve and method for manufacturing such a frame |
| WO2016150806A1 (en) | 2015-03-20 | 2016-09-29 | Jenavalve Technology, Inc. | Heart valve prosthesis delivery system and method for delivery of heart valve prosthesis with introducer sheath |
| EP3288495B1 (de) | 2015-05-01 | 2019-09-25 | JenaValve Technology, Inc. | Vorrichtung mit reduzierter herzschrittmacherrate bei herzklappenersatz |
| JP7081749B2 (ja) | 2016-05-13 | 2022-06-07 | イエナバルブ テクノロジー インク | 心臓弁プロテーゼ送達システム |
| WO2018138658A1 (en) | 2017-01-27 | 2018-08-02 | Jenavalve Technology, Inc. | Heart valve mimicry |
| CN106822903B (zh) * | 2017-02-13 | 2019-07-23 | 牡丹江医学院 | 用于治疗心衰的药物组合物及其应用 |
| WO2024102411A1 (en) | 2022-11-09 | 2024-05-16 | Jenavalve Technology, Inc. | Catheter system for sequential deployment of an expandable implant |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5684016A (en) * | 1984-04-12 | 1997-11-04 | Hoechst Aktiengesellschaft | Method of treating cardiac insufficiency |
| CA1332049C (en) * | 1988-10-07 | 1994-09-20 | Eli Lilly And Company | Eukaryotic expression |
| ZA975264B (en) * | 1996-06-17 | 1997-12-17 | Smithkline Beecham Corp | Method for treating congestive heart failure. |
| WO2000053173A1 (en) * | 1999-03-08 | 2000-09-14 | Merck & Co., Inc. | Dihydroxy open-acid and salts of hmg-co-a reductase inhibitors |
| KR101012932B1 (ko) * | 1999-04-13 | 2011-02-08 | 더 케네쓰 에스. 워렌 인스티튜트 인코포레이티드 | 말초 투여된 에리트로포에틴에 의한 흥분조직의 기능조절법 |
| EP1533380B1 (de) * | 1999-04-15 | 2009-11-04 | Crucell Holland B.V. | Verwendung von Rekombinanten Proteinen in Menschlichen Zellen |
| DE60129221D1 (de) | 2000-05-02 | 2007-08-16 | Action Pharma As | Verwendung von alpha-msh und epo zur herstellung eines arzneimittels zur prophylaxe oder behandlung von durch ischämischen zuständen bewirkten krankheiten |
| US6531121B2 (en) * | 2000-12-29 | 2003-03-11 | The Kenneth S. Warren Institute, Inc. | Protection and enhancement of erythropoietin-responsive cells, tissues and organs |
| WO2003057242A1 (en) | 2002-01-09 | 2003-07-17 | Crucell Holland B.V. | Use of erythropoietin for the preventive or curative treatment of cardiac failure |
-
2003
- 2003-01-09 WO PCT/NL2003/000011 patent/WO2003057242A1/en not_active Ceased
- 2003-01-09 CN CNA038020378A patent/CN1612747A/zh active Pending
- 2003-01-09 AT AT03703525T patent/ATE359087T1/de not_active IP Right Cessation
- 2003-01-09 DE DE60313125T patent/DE60313125T2/de not_active Expired - Lifetime
- 2003-01-09 US US10/500,913 patent/US7335490B2/en not_active Expired - Fee Related
- 2003-01-09 EP EP03703525A patent/EP1471930B1/de not_active Expired - Lifetime
- 2003-01-09 CA CA2476538A patent/CA2476538C/en not_active Expired - Fee Related
- 2003-01-09 AU AU2003206251A patent/AU2003206251B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| US20050075287A1 (en) | 2005-04-07 |
| CA2476538C (en) | 2012-07-17 |
| EP1471930B1 (de) | 2007-04-11 |
| CN1612747A (zh) | 2005-05-04 |
| EP1471930A1 (de) | 2004-11-03 |
| DE60313125D1 (de) | 2007-05-24 |
| DE60313125T2 (de) | 2007-12-20 |
| CA2476538A1 (en) | 2003-07-17 |
| AU2003206251B2 (en) | 2008-03-13 |
| AU2003206251A1 (en) | 2003-07-24 |
| WO2003057242A1 (en) | 2003-07-17 |
| US7335490B2 (en) | 2008-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE359087T1 (de) | Verwendung von erythropoietin zur behandlung oder vorbeugung von herzversagen | |
| ATE533484T1 (de) | Verwendung von rotigotin zur behandlung oder zur prävention des dopaminergen neuronenverlustes | |
| NO20061325L (no) | Kombinasjon av legemidler for behandling av neoplasmer | |
| DE59907752D1 (de) | Verwendung von erythropoietin oder erythropoietin-derivaten zur behandlung von cerebralen ischämien | |
| DE60113548D1 (de) | Cyanomethyl-substituierte thiazolium- und imidazolium-verbindungen und behandlung von erkrankungen im zusammenhang mit proteinalterung | |
| ATE408601T1 (de) | Fredericamycin-derivate | |
| DE502005010615D1 (de) | Mittel zur behandlung von entzündlichen erkrankungen | |
| WO2003092617A3 (en) | Combinations for the treatment of inflammatory skin disorders | |
| DE69840497D1 (de) | Verwendung von Aplidine zur Behandlung von kardiovaskulären Erkrankungen | |
| PH12021553102A1 (en) | Methods of treating fabry disease in patients having renal impairment | |
| ATE420099T1 (de) | Medikament zur wachstumsinhibierung von tumoren | |
| BRPI0415756A (pt) | lipólise medicamentosa local, dirigida | |
| BRPI0509543A (pt) | derivados de tiazolopiridina, condições farmacêuticas que contêm os mesmos e métodos para tratar condições mediadas por glucocinase | |
| ATE429916T1 (de) | Verwendung von sulfonamid-derivaten bei der behandlung von adipositas oder zur verringerung der nahrungsaufnahme | |
| PH12014500232A1 (en) | Left ventricular diastolic function improving agent | |
| CY1111353T1 (el) | Χρηση ενωσεων κααλαλιδης για την παραγωγη φαρμακου για τη θεραπεια της ψωριασης | |
| WO2004006849A3 (en) | Combinations of drugs for the treatment of neoplasms | |
| ATE553760T1 (de) | Verwendung von alverin zur behandlung von hauterkrankungen | |
| DE60200160D1 (de) | Verwendung von Cilobradine oder pharmazeutisch akzeptablen Salze zur Behandlung oder Prävention von Herzversagen | |
| DE60326742D1 (de) | Piperazin und piperadin-derivate für die behandlung von neurologischen krankheiten | |
| ATE206052T1 (de) | Verwendung von sphingosin-1-phosphat, sphingosin- 1-phosphat-derivaten und/oder deren gemische zur behandlung von entzündlichen hautkrankheiten | |
| DE602008003411D1 (de) | Verwendung von d-ribose zur behandlung von vorhofflimmern | |
| ATE239492T1 (de) | Verwendung von einem bpi protein zur herstellung eines medikamentes zur behandlung von chronischen herzerkrankungen | |
| ATE337004T1 (de) | Verwendung von mangafodipir zur behandlung der hepatozellularen insuffizienz | |
| ATE369849T1 (de) | Haloacetamidobenzoesäure derivate und deren verwendung zur behandlung von parasitären erkrankungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |